MVM Partners LLP is a private equity and venture capital firm that focuses on investments in early-stage to growth-stage healthcare and life sciences companies. Established in 1997 and based in London with an office in Boston, MVM specializes in a wide range of sectors including biotechnology, specialty pharmaceuticals, medical technology, diagnostics, and digital health. The firm typically invests between £5 million and $30 million per company, aiming for aggregate investments of $10 million to $50 million over the life of its portfolio. MVM prioritizes companies with innovative, patent-protected technologies that address significant medical needs and market opportunities. The firm operates flexibly, investing globally, particularly in Western Europe and the Eastern United States, and often seeks board representation in its portfolio companies. MVM manages four funds totaling over $700 million and has a diverse investment strategy that includes both equity and debt instruments.
Nalu Medical is an early-stage company that develops a range of medical devices. Their vision to modernize and improve the technology in medical devices, thus improving the lives of people. The Nalu neurostimulation system is a battery-free, micro-implantable pulse generator (iPG) currently cleared by the FDA for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) for mitigating chronic pain. The company was founded in 2014 and is based in Carlsbad, California.
GeNO is a biopharmaceutical company focused on the design, development and commercialization of next-generation products to address unmet medical needs of patients with a variety of pulmonary and cardiac diseases. We are currently developing inhaled nitric oxide (NO) products for use in both the hospital setting and for longer-term applications outside of the hospital setting. These products, which are based on our GeNOsyl™ drug delivery technology, are comprised of a single-use drug cassette and either a portable console or wearable controller. Our technology is designed to deliver NO safely for a variety of therapeutic indications and to provide clinicians with a solution that is more user-friendly than currently available NO delivery systems.
Swift Health Systems Inc. is a medical device company based in Irvine, California, that specializes in developing innovative orthodontic solutions. The company's flagship product, INBRACE, is an invisible orthodontic system designed to correct malocclusion by being discreetly positioned behind the teeth. INBRACE employs patented self-guiding technology that utilizes light and continuous forces to gently adjust teeth, minimizing discomfort and reducing the frequency of doctor visits. FDA registered, INBRACE aims to make orthodontic treatment more appealing by addressing common patient concerns and facilitating practice growth for clinicians. The system integrates digital treatment planning, computer modeling, and direct digital manufacturing to offer a scalable and personalized approach to a wide range of orthodontic cases, thereby raising the standard of care in the field.
eXmoor Pharma is a consultancy focused on cell and gene therapies, as well as biopharmaceuticals. The company operates a contract development and manufacturing business that provides a variety of services tailored to the needs of its clients. These services include manufacturing strategy, process development consultancy, and bioprocess engineering. By leveraging its expertise, eXmoor Pharma helps organizations design and implement projects that align with their specific goals and commercial objectives in the rapidly evolving field of advanced therapy medicinal products (ATMPs).
GT Medical Technologies, Inc. is a medical device company based in Tempe, Arizona, focused on enhancing the treatment options for patients with brain tumors. Founded in 2017, the company has developed GammaTile, an innovative medical device that integrates a biocompatible collagen matrix with brachytherapy radiation seeds. This technology is designed to address the limitations of existing treatments for recurrent brain tumors, providing a conformable and bioresorbable solution that can potentially prevent disease progression and improve patient quality of life. GammaTile has received multiple patents and has shown promise in clinical trials, with significant improvements observed in patients treated at the Barrow Neurological Institute. This approach aims to revolutionize care for the estimated 176,000 individuals diagnosed with brain tumors annually in the United States.
Paragon 28, Inc. is a medical device company specializing in products for foot and ankle surgery. Founded in 2010 and headquartered in Englewood, Colorado, with an additional office in Dublin, Ireland, the company develops and sells a comprehensive range of surgical solutions. Its offerings include plates, screws, staples, and nails designed for various orthopedic procedures, such as arthrodesis, hallux valgus correction, and fracture fixation. Notable products include the PHANTOM Lapidus Intramedullary Nail, the Proximal Rotational Metatarsal Osteotomy system, and the JAWS Nitinol Staple System. Paragon 28 aims to address the specific needs of patients and procedures, with nearly 80 product systems in its portfolio, primarily generating revenue from the United States market.
SkyCell AG is a Swiss company that specializes in the design and manufacture of temperature-controlled containers for transporting sensitive pharmaceutical products. Founded in 2013 and headquartered in Zurich, SkyCell focuses on providing solutions that ensure the safe delivery of temperature-sensitive goods. The containers, which include various models such as the SkyCell 2500C and SkyCell 1500C, are equipped with IoT sensors that connect to a data cloud, allowing for real-time monitoring and intervention. The company's technology employs blockchain for enhanced tracking and data security, facilitating end-to-end visibility throughout the supply chain. SkyCell's commitment to sustainability is evident in its efforts to reduce carbon dioxide emissions while addressing logistical challenges faced by global pharma companies.
MDxHealth is a molecular diagnostics company focused on developing and commercializing advanced tests to assist in cancer detection and treatment. The company offers a range of products, including ConfirmMDx, a prostate cancer tissue test aimed at addressing false-negative biopsy results; SelectMDx, a non-invasive urine test for prostate cancer; and AssureMDx, a liquid biopsy test for bladder cancer that aids in cystoscopy decisions. Additionally, MDxHealth provides PredictMDx, a tissue methylation test designed to inform treatment decisions for glioblastoma. Founded in 2003 and headquartered in Herstal, Belgium, with offices in Irvine, California, and Nijmegen, the Netherlands, MDxHealth operates internationally, serving markets across Europe and the United States. The company specializes in epigenetic and molecular technologies to enhance the accuracy of cancer diagnoses and tailor personalized treatment strategies for patients.
Providence Medical Technology is a privately-held medical device company focused on innovative solutions for cervical spinal conditions. The company has pioneered a proprietary approach to cervical fusion and has developed surgical instrumentation and implants that offer unique benefits to the $2 billion worldwide cervical spine market. The Providence family of products includes the DTRAX® Spinal Instrumentation System, CAVUX® intervertebral implants, and the ALLY® line of bone and facet screws. All products are shipped-sterile and single-use to maximize perioperative efficiency and ensure consistent quality and performance.
Zipline Medical, Inc. specializes in the development and marketing of non-invasive skin closure solutions, specifically through its patented Zip Surgical Skin Closure product. This innovative technology addresses the need for rapid, easy-to-use skin closure in various medical fields, including electrophysiology, cardiology, orthopedics, dermatology, emergency medicine, plastic and reconstructive surgery, obstetrics and gynecology, and general surgery. The company's PRELOC™ technology platform is designed to provide uniform closure forces while reducing tension that can lead to scarring, aiming to combine the efficiency of staples with the aesthetic benefits of sutures. Founded in 2009 and based in Campbell, California, Zipline Medical operates as a subsidiary of Stryker Corporation, leveraging its location in Silicon Valley to draw on expertise in medical device research and development. The company's focus on enhancing surgical procedures through improved skin closure techniques positions it as a valuable player in the medical device industry.
VitalConnect specializes in wearable biosensor technology aimed at enhancing patient monitoring both in hospitals and remotely. The company utilizes its expertise in biomedical engineering, data analytics, and chip design to develop products that continuously monitor vital signs through an adhesive patch. These innovations include the Vista Solution, which provides healthcare professionals with 24/7 access to patient health data via an online portal, tracking 11 vital signs and offering predictive analytics. The VitalPatch biosensor specifically measures critical parameters such as EKG, heart rate, respiratory rate, and body temperature, facilitating immediate responses to urgent health situations. By combining these technologies, VitalConnect's solutions improve patient mobility and comfort while enabling clinicians to optimize treatment through comprehensive patient insights, ultimately leading to better health outcomes and reduced economic burdens.
Cheetah’s proprietary CHEETAH NICOM system is CE marked and FDA cleared. It is the only non-invasive cardiac output monitor with substantial equivalence to the Swan Ganz thermodilution system for U.S. regulatory purposes. The CHEETAH NICOM is now used by leading medical centers around the globe providing clinicians with invaluable clinical information in complicated scenarios. Cheetah Medical is committed to ongoing research and development and close cooperation with clinicians.
Vertos Medical Inc. is a medical device company based in Aliso Viejo, California, founded in 2005 by Dr. Dave Solsberg and Dr. Don Schomer. The company specializes in developing minimally invasive treatments for lumbar spinal stenosis (LSS), a common spinal condition. Its flagship product, the mild device, facilitates an outpatient treatment that is fluoroscopically guided and does not require the use of implants. This device includes components such as tissue sculptors, portals, trocars, and surgical clamps, allowing physicians to perform lumbar decompression procedures with local anesthesia. By restoring space in the spinal canal and alleviating pressure on the nerves, Vertos Medical's solutions aim to improve patient mobility and quality of life. The company's devices are primarily offered in the United States.
Zipline Medical, Inc. specializes in the development and marketing of non-invasive skin closure solutions, specifically through its patented Zip Surgical Skin Closure product. This innovative technology addresses the need for rapid, easy-to-use skin closure in various medical fields, including electrophysiology, cardiology, orthopedics, dermatology, emergency medicine, plastic and reconstructive surgery, obstetrics and gynecology, and general surgery. The company's PRELOC™ technology platform is designed to provide uniform closure forces while reducing tension that can lead to scarring, aiming to combine the efficiency of staples with the aesthetic benefits of sutures. Founded in 2009 and based in Campbell, California, Zipline Medical operates as a subsidiary of Stryker Corporation, leveraging its location in Silicon Valley to draw on expertise in medical device research and development. The company's focus on enhancing surgical procedures through improved skin closure techniques positions it as a valuable player in the medical device industry.
Valneva SE is a specialty vaccine company dedicated to the development and commercialization of vaccines for infectious diseases that lack adequate solutions. The company offers two commercial vaccines for travelers: IXIARO/JESPECT, which protects against Japanese encephalitis, and DUKORAL, aimed at preventing cholera and certain types of diarrhea. Valneva is also advancing several vaccine candidates, including the only developmental vaccine for Lyme disease and a single-shot vaccine for chikungunya. Founded in 1999, Valneva operates in multiple countries, including Austria, Canada, France, Sweden, the United Kingdom, and the United States. The company is involved in a collaboration with Dynavax Technologies Corporation to further vaccine development for COVID-19. Valneva's focus is on addressing urgent public health needs through innovative vaccine solutions.
Providence Medical Technology is a privately-held medical device company focused on innovative solutions for cervical spinal conditions. The company has pioneered a proprietary approach to cervical fusion and has developed surgical instrumentation and implants that offer unique benefits to the $2 billion worldwide cervical spine market. The Providence family of products includes the DTRAX® Spinal Instrumentation System, CAVUX® intervertebral implants, and the ALLY® line of bone and facet screws. All products are shipped-sterile and single-use to maximize perioperative efficiency and ensure consistent quality and performance.
BioTheranostics, Inc. is a commercial-stage molecular diagnostics company focused on developing and providing proprietary diagnostic tests that aid physicians in making informed decisions regarding cancer treatment. The company offers several key products, including the Breast Cancer Index, which assists oncologists in determining the appropriateness of extended endocrine therapy for patients with estrogen receptor-positive breast cancer. Additionally, CancerTYPE ID delivers critical genomic information for the diagnosis and management of metastatic cancer, while the bioT3 metastatic cancer solution integrates precise molecular diagnosis with extensive biomarker data to enhance treatment options for metastatic cancer patients. Founded in 1996 and headquartered in San Diego, California, BioTheranostics aims to support personalized medicine by ensuring that every patient receives a tailored care plan.
Zipline Medical, Inc. specializes in the development and marketing of non-invasive skin closure solutions, specifically through its patented Zip Surgical Skin Closure product. This innovative technology addresses the need for rapid, easy-to-use skin closure in various medical fields, including electrophysiology, cardiology, orthopedics, dermatology, emergency medicine, plastic and reconstructive surgery, obstetrics and gynecology, and general surgery. The company's PRELOC™ technology platform is designed to provide uniform closure forces while reducing tension that can lead to scarring, aiming to combine the efficiency of staples with the aesthetic benefits of sutures. Founded in 2009 and based in Campbell, California, Zipline Medical operates as a subsidiary of Stryker Corporation, leveraging its location in Silicon Valley to draw on expertise in medical device research and development. The company's focus on enhancing surgical procedures through improved skin closure techniques positions it as a valuable player in the medical device industry.
Onbone Oy is a Finnish medical technology company based in Helsinki, specializing in the development and marketing of innovative Woodcast products designed for orthopedic and traumatology applications. The Woodcast product line includes various items such as ribbons, colored splints, folded splints, and heating devices, which are aimed at improving patient care and treatment outcomes. The company distributes its products through local distributors in multiple countries, including Finland, Germany, Sweden, the Netherlands, and Great Britain. Established in 2008, Onbone Oy was previously known as Injectobone Finland Oy before rebranding in January 2010. With a dedicated team of eleven employees, Onbone focuses on providing user-friendly solutions in the medical technology sector.
AmbioPharm, Inc. specializes in the contract manufacturing of peptides and biopharmaceuticals for pharmaceutical and biotechnology companies. Founded in 2006 and based in North Augusta, South Carolina, the company produces active pharmaceutical ingredients (APIs), generic peptides, and custom peptides for various applications, including pre-clinical in-vitro, medicinal, and toxicology programs. AmbioPharm's offerings include GLP-grade peptides and non-peptidic small molecules, as well as conjugations to proteins and other compounds. The company is involved in the development of generic peptide drugs and supports clinical studies across a range of therapeutic areas, such as ophthalmology, oncology, and infectious diseases. With manufacturing facilities in both South Carolina and Shanghai, China, AmbioPharm employs a responsive business model and efficient manufacturing processes to help clients expedite their peptide projects from preclinical and clinical stages to commercial production.
Vascular Pathways is a privately held medical device company founded by Amir Belson, M.D. The company specializes in the commercialization of its flagship product, the Rapid IntraVascular Start (RIVS) catheter. This FDA-cleared device is designed to facilitate rapid, safe, and successful peripheral intravenous (IV) insertion, addressing a critical need in medical settings. By streamlining the process of IV placement, Vascular Pathways aims to enhance patient care and improve outcomes in various healthcare environments.
Tarsa Therapeutics, Inc. develops therapies for the treatment and prevention of osteoporosis and related bone diseases in women. It develops TBRIA, an oral formulation of salmon calcitonin used in the treatment of postmenopausal osteoporosis. The company offers clinical programs, such as osteoporosis treatment and osteoporosis prevention programs. Tarsa Therapeutics, Inc. was formerly known as Boneco, Inc. The company was founded in 2009 and is based in Philadelphia, Pennsylvania.
Wilson Therapeutics is a biopharmaceutical company located in Stockholm, Sweden, focusing on the development of innovative therapies for rare diseases, particularly Wilson Disease. The company’s primary product, Decuprate®, is being investigated as a new treatment option for this condition and is currently undergoing evaluation in a Phase II clinical study involving patients with Wilson Disease. By targeting copper-mediated disorders, Wilson Therapeutics aims to address unmet medical needs in this specialized area of healthcare.
Cheetah’s proprietary CHEETAH NICOM system is CE marked and FDA cleared. It is the only non-invasive cardiac output monitor with substantial equivalence to the Swan Ganz thermodilution system for U.S. regulatory purposes. The CHEETAH NICOM is now used by leading medical centers around the globe providing clinicians with invaluable clinical information in complicated scenarios. Cheetah Medical is committed to ongoing research and development and close cooperation with clinicians.
Horizon Discovery Group PLC is a UK life science company that uses gene editing and gene modulation platforms to produce cells, applying them in research and clinical applications that advance human health. The Company’s gene editing and gene modulation platform, are able to alter almost any DNA sequence or RNA transcription, has generated a catalogue of over 1,000,000 cell and reagent products that help researchers recapitulate the genetic and protein anomalies found in diseases like cancer. These models have been adopted by c12, 000 organizations to better understand of the predictors and drivers of disease and drug response, and by Horizon in a range of services offered to customers, as well as in the Company’s own research R&D pipeline.
Cheetah’s proprietary CHEETAH NICOM system is CE marked and FDA cleared. It is the only non-invasive cardiac output monitor with substantial equivalence to the Swan Ganz thermodilution system for U.S. regulatory purposes. The CHEETAH NICOM is now used by leading medical centers around the globe providing clinicians with invaluable clinical information in complicated scenarios. Cheetah Medical is committed to ongoing research and development and close cooperation with clinicians.
eZono is a young dynamic company focused on point of care solutions. Based in Jena, Germany, eZono brings together a multicultural team of experts, bringing a diverse and fresh approach to ultrasound guidance of interventional procedures.
Founded in 2004, eZono AG is a different kind of ultrasound company, one that empowers non-traditional ultrasound users to incorporate sonography in their daily work. This enables their customers to improve clinical outcomes, enhance patient satisfaction and in particular lower cost. As a result they bring not only affordable portable sonography technology to specific applications but also makes it easy for instance for anesthetists to operate – reducing drastically their learning effort.
Tarsa Therapeutics, Inc. develops therapies for the treatment and prevention of osteoporosis and related bone diseases in women. It develops TBRIA, an oral formulation of salmon calcitonin used in the treatment of postmenopausal osteoporosis. The company offers clinical programs, such as osteoporosis treatment and osteoporosis prevention programs. Tarsa Therapeutics, Inc. was formerly known as Boneco, Inc. The company was founded in 2009 and is based in Philadelphia, Pennsylvania.
Patient Connect Service Limited is a health information provider based in Godalming, United Kingdom, that specializes in delivering evidence-based clinical messages to patients and healthcare providers. The company partners with pharmacy chains and pharmaceutical firms to enhance patient education regarding medications and disease management. Through its platform, Patient Connect offers tools such as patient information leaflets, alert services, and support programs that help patients manage their medications effectively. Additionally, pharmacists can access and print clinically relevant information for patients, facilitating better communication and care. Over the past three years, the company has executed numerous projects for leading pharmaceutical companies, solidifying its position in the market. Patient Connect was established in 2004 and was formerly known as Health Information Limited before rebranding in 2012.
Horizon Discovery Group PLC is a UK life science company that uses gene editing and gene modulation platforms to produce cells, applying them in research and clinical applications that advance human health. The Company’s gene editing and gene modulation platform, are able to alter almost any DNA sequence or RNA transcription, has generated a catalogue of over 1,000,000 cell and reagent products that help researchers recapitulate the genetic and protein anomalies found in diseases like cancer. These models have been adopted by c12, 000 organizations to better understand of the predictors and drivers of disease and drug response, and by Horizon in a range of services offered to customers, as well as in the Company’s own research R&D pipeline.
Beacon Endoscopic (BE) is a Boston based medical device company innovating in existing interventional endoscopic procedures and developing next generation devices to change the paradigm of surgery
AccuVein Inc. is a manufacturer of vein visualization solutions aimed at improving vascular access for healthcare professionals. Founded in 2006 and based in Medford, New York, the company specializes in portable, non-contact devices that illuminate peripheral veins, enabling practitioners to see a detailed map of veins beneath the skin. Its flagship product, the AV400, is designed to enhance procedures such as blood draws, IV infusions, and cosmetic injections by allowing accurate vein identification and access. AccuVein's offerings also include various hands-free and wheeled solutions that cater to different medical settings, including surgery centers, imaging centers, and long-term care facilities. The company distributes its products through a network of sales representatives and distributors both in the United States and internationally.
Vantia Ltd is a pharmaceutical company based in Southampton, United Kingdom, that specializes in the development of novel small molecule drugs aimed at addressing significant unmet medical needs. Founded in 2007, the company has a strong clinical pipeline featuring drug candidates such as Fedovapagon (VA106483), which targets nocturia, a condition characterized by frequent nighttime urination, and VA111913, aimed at treating dysmenorrhea, a painful condition associated with menstrual cycles. These conditions affect millions of people and are often inadequately managed, representing substantial market opportunities. Vantia Ltd plans to advance its proprietary drug candidates through Phase II clinical trials and seeks to commercialize them through strategic partnerships, supported by investments from specialist life science firms.
Vascular Pathways is a privately held medical device company founded by Amir Belson, M.D. The company specializes in the commercialization of its flagship product, the Rapid IntraVascular Start (RIVS) catheter. This FDA-cleared device is designed to facilitate rapid, safe, and successful peripheral intravenous (IV) insertion, addressing a critical need in medical settings. By streamlining the process of IV placement, Vascular Pathways aims to enhance patient care and improve outcomes in various healthcare environments.
SOLX, Inc. is a medical device company based in Waltham, Massachusetts, specializing in the development of innovative solutions for glaucoma treatment. Founded in 2000, the company focuses on creating products that measure and reduce intraocular pressure (IOP) in the eye. Its flagship product, the SOLX Gold Shunt, is a minimally invasive surgical device designed to facilitate the drainage of fluid from the anterior chamber to the suprachoroidal space, effectively addressing glaucoma while minimizing the risks associated with traditional filtering surgeries, such as bleb-related complications. Through its advancements, SOLX aims to improve the management of glaucoma and enhance patient outcomes.
Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Stamford, Connecticut, specializing in the development of innovative therapies for pain and pruritus. The company's lead product candidate, CR845 (difelikefalin), is being tested in Phase III clinical trials for chronic kidney disease-associated pruritus in patients undergoing hemodialysis. Additionally, the company is advancing Oral KORSUVA, which has completed Phase II trials for pruritus in chronic kidney disease and is also being evaluated for its effects on pruritus related to chronic liver disease and atopic dermatitis. Cara is also working on CR845/difelikefalin injection, which has completed Phase II/III trials for acute post-operative pain. The company has established licensing agreements with Maruishi Pharmaceutical Co., Ltd. in Japan and Chong Kun Dang Pharmaceutical Corporation in South Korea for the development and commercialization of CR845/difelikefalin. With a focus on leveraging proprietary drug-screening technology, Cara aims to build a pipeline of first-in-class therapeutic candidates targeting pain and inflammation.
Cheetah’s proprietary CHEETAH NICOM system is CE marked and FDA cleared. It is the only non-invasive cardiac output monitor with substantial equivalence to the Swan Ganz thermodilution system for U.S. regulatory purposes. The CHEETAH NICOM is now used by leading medical centers around the globe providing clinicians with invaluable clinical information in complicated scenarios. Cheetah Medical is committed to ongoing research and development and close cooperation with clinicians.
Tarsa Therapeutics, Inc. develops therapies for the treatment and prevention of osteoporosis and related bone diseases in women. It develops TBRIA, an oral formulation of salmon calcitonin used in the treatment of postmenopausal osteoporosis. The company offers clinical programs, such as osteoporosis treatment and osteoporosis prevention programs. Tarsa Therapeutics, Inc. was formerly known as Boneco, Inc. The company was founded in 2009 and is based in Philadelphia, Pennsylvania.
Clavis Pharma ASA, a healthcare and clinical-stage pharmaceutical company, engages in the discovery and development of novel small molecule therapeutics for cancer and other unmet medical needs. It also engages in the development of new and improved pharmaceuticals based on its lipid vector technology (LVT). The company has three anti-cancer drugs in clinical development for various indications, and a pipeline of other drug candidates within oncology, virology, and anti-inflammatory diseases. Its products primarily include Elacytarabine, which is in the Phase II clinical trials for various solid tumor indications, as well as in Phase I/II clinical trials for the treatment of blood cancers, including leukemia; Intravenous CP-4126, a multicentre trial open to patients with any type of solid tumours that is in Phase I clinical trials; Oral CP-4126, an analogue of gemcitabine, which is Phase I clinical trial; and CP-4200, an epigenetic modulator that is in preclinical stage for the treatment of hematological malignancies, such as MDS and leukemia. The company�s products also include CP-4010, an analogue of acyclovir that is in the Phase I clinical trial for the treatment of herpes labialis and herpes genitalis; and CP-4018, an analogue of gancyclovir, which is in the preclinical stage. In addition, its products comprise CP-4033, CP-4112, and CP-4114 that are the analogues of ribavirin, betamethason, and prednisolon respectively. The company has a collaboration agreement with Mount Sinai School of Medicine for the design and testing of new LVT based drug candidates for the treatment of cancer and haematological malignancies. Clavis Pharma ASA was founded in 2001 and is headquartered in Oslo, Norway.
BioVex is a biotechnology company focused on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. Their cancer program, OncoVEXGM-CSF, is a oncolytic vaccine or cancer destroying virus technology that works by replicating and spreading within solid tumors, causing the death of cancer cells while leaving surrounding healthy cells unharmed. The attenuated virus has also been constructed to induce a powerful systemic anti tumor immune response. OncoVEXGM-CSF has now been tested in >110 patients in a broad range of solid tumors including melanoma, head & neck cancer, breast cancer and pancreatic cancer. Both the direct cell killing and systemic immune mediated mechanisms of action of OncoVEX have been clearly validated in the clinic; OncoVEX routinely destroys tumors it is directly injected into and has led to overall disease responses in multiple patients in Phase II testing. Tumors resolved through OncoVEX treatment have not been known to recur.
BioVex is a biotechnology company focused on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. Their cancer program, OncoVEXGM-CSF, is a oncolytic vaccine or cancer destroying virus technology that works by replicating and spreading within solid tumors, causing the death of cancer cells while leaving surrounding healthy cells unharmed. The attenuated virus has also been constructed to induce a powerful systemic anti tumor immune response. OncoVEXGM-CSF has now been tested in >110 patients in a broad range of solid tumors including melanoma, head & neck cancer, breast cancer and pancreatic cancer. Both the direct cell killing and systemic immune mediated mechanisms of action of OncoVEX have been clearly validated in the clinic; OncoVEX routinely destroys tumors it is directly injected into and has led to overall disease responses in multiple patients in Phase II testing. Tumors resolved through OncoVEX treatment have not been known to recur.
Heptares Therapeutics Ltd. is a clinical-stage drug discovery company based in Welwyn Garden City, United Kingdom, founded in 2007. The company specializes in developing novel small-molecule medicines that target G protein-coupled receptors (GPCRs), a significant family of druggable targets associated with various human diseases. Heptares has pioneered a proprietary technology for producing purified, stabilized, and functional GPCRs, known as Stabilised Receptors (StaRs), which addresses a key challenge in drug development. Its research focuses on treatments for conditions such as Alzheimer's disease, ADHD, diabetes, schizophrenia, and migraines. Heptares maintains strategic collaborations with several organizations, including Pfizer and Kymab, to enhance its drug discovery efforts. As of 2015, Heptares operates as a subsidiary of Sosei Group Corporation.
Serentis develops medical products and drugs. Its products include SRD441, a novel compound that targets endogenous pro-inflammatory and staphylococcus aureus-derived proteases; and SRD174, a topical product designed to produce relief of pruritus. The company’s research programs include SRD326, a topically-applied product for relief from symptoms of Raynaud’s phenomenon; and SRD285 which provides an approach to wound care, promoting enhanced wound healing and local analgesia. Serentis was founded in 2006 and is based in Cambridge, United Kingdom.
PregLem is a Swiss-based biopharmaceutical company focused on the development and commercialization of innovative drugs specifically for women's reproductive health. The company aims to address unmet medical needs in this field by creating advanced therapies that enhance the quality of care for women. Through its specialized approach, PregLem is committed to improving treatment options and outcomes for various reproductive health conditions.
Heptares Therapeutics Ltd. is a clinical-stage drug discovery company based in Welwyn Garden City, United Kingdom, founded in 2007. The company specializes in developing novel small-molecule medicines that target G protein-coupled receptors (GPCRs), a significant family of druggable targets associated with various human diseases. Heptares has pioneered a proprietary technology for producing purified, stabilized, and functional GPCRs, known as Stabilised Receptors (StaRs), which addresses a key challenge in drug development. Its research focuses on treatments for conditions such as Alzheimer's disease, ADHD, diabetes, schizophrenia, and migraines. Heptares maintains strategic collaborations with several organizations, including Pfizer and Kymab, to enhance its drug discovery efforts. As of 2015, Heptares operates as a subsidiary of Sosei Group Corporation.
PregLem is a Swiss-based biopharmaceutical company focused on the development and commercialization of innovative drugs specifically for women's reproductive health. The company aims to address unmet medical needs in this field by creating advanced therapies that enhance the quality of care for women. Through its specialized approach, PregLem is committed to improving treatment options and outcomes for various reproductive health conditions.
Serentis develops medical products and drugs. Its products include SRD441, a novel compound that targets endogenous pro-inflammatory and staphylococcus aureus-derived proteases; and SRD174, a topical product designed to produce relief of pruritus. The company’s research programs include SRD326, a topically-applied product for relief from symptoms of Raynaud’s phenomenon; and SRD285 which provides an approach to wound care, promoting enhanced wound healing and local analgesia. Serentis was founded in 2006 and is based in Cambridge, United Kingdom.
Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Stamford, Connecticut, specializing in the development of innovative therapies for pain and pruritus. The company's lead product candidate, CR845 (difelikefalin), is being tested in Phase III clinical trials for chronic kidney disease-associated pruritus in patients undergoing hemodialysis. Additionally, the company is advancing Oral KORSUVA, which has completed Phase II trials for pruritus in chronic kidney disease and is also being evaluated for its effects on pruritus related to chronic liver disease and atopic dermatitis. Cara is also working on CR845/difelikefalin injection, which has completed Phase II/III trials for acute post-operative pain. The company has established licensing agreements with Maruishi Pharmaceutical Co., Ltd. in Japan and Chong Kun Dang Pharmaceutical Corporation in South Korea for the development and commercialization of CR845/difelikefalin. With a focus on leveraging proprietary drug-screening technology, Cara aims to build a pipeline of first-in-class therapeutic candidates targeting pain and inflammation.
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutics/pharmaceuticals to treat cardiovascular and metabolic diseases. It develops lomitapide/AEGR-733, a microsomal triglyceride transfer protein inhibitor small molecule drug for decreasing serum lipids, including cholesterol and triglycerides, as well as to treat atherosclerosis, dyslipidemia, obesity, and pancreatitis. The company also focuses on products for the evaluation and treatment of hyperlipidemia. Aegerion Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Bridgewater, New Jersey.
BioXell was founded in 2002 as a spinout of Roche Milano Ricerche, a leading biomedical research institute created ten years earlier that focused on chronic inflammatory disease and autoimmunity. The idea to create BioXell originated with Francesco Sinigaglia, founder and director of the Milan-based research institute, following a scientific career path that took him to the University College in London, the Basel Institute of Immunology and the Hoffmann-La Roche research units in Basel. Dr. Sinigaglia, former CEO, approached Roche with his challenging project and a year later BioXell was spun off, with $22m invested by MPM Capital, Index Ventures and Life Science Partners.
As of August 4, 2008, Spherics, Inc. went out of business. Spherics, Inc., a pharmaceutical company, engages in developing and manufacturing oral pharmaceutical products for central nervous system conditions, gastrointestinal disorders, and cancer. It develops oral systems based on the application of bioadhesive polymers to oral dosage forms. The company also provides products for neurological disorders, such as Alzheimer's, Parkinson's, and multiple sclerosis, as well as for stroke, epilepsy, chronic pain, and migraine. The company was founded in 1997 and is headquartered in Mansfield, Massachusetts.
BioXell was founded in 2002 as a spinout of Roche Milano Ricerche, a leading biomedical research institute created ten years earlier that focused on chronic inflammatory disease and autoimmunity. The idea to create BioXell originated with Francesco Sinigaglia, founder and director of the Milan-based research institute, following a scientific career path that took him to the University College in London, the Basel Institute of Immunology and the Hoffmann-La Roche research units in Basel. Dr. Sinigaglia, former CEO, approached Roche with his challenging project and a year later BioXell was spun off, with $22m invested by MPM Capital, Index Ventures and Life Science Partners.
Evotec Neurosciences
Series A in 2004
Evotec Neurosciences GmbH engages in the discovery and development of small molecule drugs.
Xention Limited, a biopharmaceutical company, specializes in the discovery and development of ion channel-modulating drugs. It offers drugs for the treatment of atrial fibrillation, overactive bladder, pain, and autoimmune diseases. Xention Limited was formerly known as Xention Discovery Ltd. and later changed its name to Xention Limited in October 2006. The company was founded in 2002 and is based in Cambridge, the United Kingdom.
Oxxon Therapeutics™ (Oxxon) is a company developing the next generation of innovative antigen-specific immunotherapies to treat patients with chronic infectious diseases and cancer. To date, the company has built an initial pipeline through its patented Hi-8™ PrimeBoost immunotherapy platform, an approach that allows the rapid development of products to selectively stimulate and enhance potent immune responses against disease. The company has successfully completed phase II clinical programmes in melanoma and hepatitis B and has a third development programme underway in HIV. In addition, the company intends to leverage its enabling platform through partnerships with companies developing therapeutic and preventative vaccine products.
Avantium is a technology company based in Amsterdam, specializing in advanced high-throughput research and development for the energy, chemicals, and pharmaceutical sectors. It employs proprietary technology that accelerates and reduces the costs associated with developing new products and processes. Avantium's innovative approach to experiment design and data analysis enhances its success rate in delivering effective solutions. The company has successfully collaborated with over 70 global clients, showcasing the commercial viability of its services. Avantium focuses on two primary areas: developing biofuels and bio-based chemicals, as well as new crystal forms of patented drugs. Its business model includes a strong emphasis on expanding its patent portfolio and establishing partnerships that add value. Additionally, Avantium operates through segments such as R&D Solutions, Renewable Chemistries, and Renewable Polymers, with the R&D Solutions segment generating the majority of its revenue. The company is supported by a team of experts in various fields, including catalysis, organic chemistry, and software development, who work closely with partner organizations to drive innovation in sustainable chemistry.
BioXell was founded in 2002 as a spinout of Roche Milano Ricerche, a leading biomedical research institute created ten years earlier that focused on chronic inflammatory disease and autoimmunity. The idea to create BioXell originated with Francesco Sinigaglia, founder and director of the Milan-based research institute, following a scientific career path that took him to the University College in London, the Basel Institute of Immunology and the Hoffmann-La Roche research units in Basel. Dr. Sinigaglia, former CEO, approached Roche with his challenging project and a year later BioXell was spun off, with $22m invested by MPM Capital, Index Ventures and Life Science Partners.
De Novo Pharmaceuticals
Series B in 2001
De Novo Pharmaceuticals is an emerging computational drug design company. De Novo Pharmaceuticals uses its proprietary computational software for drug design to create novel, patentable lead molecules as candidates for drug development. De Novo's proprietary algorithms can convert information from structural genomics and medicinal chemistry rapidly into new chemical designs, maximising value within a pharmaceutical partner's research portfolio. De Novo's drug discovery partners include British Biotechnology, Aventis Pharmaceuticals and NV Organon.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.